C-Path’s TRxA awards $250,000 grant to develop novel treatment for type 1 diabetes

Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D).